| Autor: |
Williams, Casey, Cannella, Carrie |
| Předmět: |
|
| Zdroj: |
Hospital Pharmacy; Jul2008, Vol. 43 Issue 7, p544-545, 2p |
| Abstrakt: |
The article focuses on posaconazole, marketed under the brand name Noxafil, that was approved for use in the U.S. in September 2006 for the treatment and prevention of invasive fungal infections (IFI). The clinical practice guidelines released by the Infectious Disease Society of America in February 2008 recommended the use of posaconazole for the treatment of aspergillosis. It mentions that the average wholesale price of the drug was $634.79 per 105 millilambert (mL) bottle. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
